Bottom line
PHSTX vs ETHSX: the short answer
PHSTX (Putnam Global Health Care Fund) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) are both mutual funds.
But PHSTX is far broader, holding 115 positions to 42 for ETHSX, so beyond the top names it adds exposure ETHSX doesn't have.
PHSTX is cheaper at 1.04% vs 1.18% — a difference of $14 a year per $10,000 invested.
Over five years, PHSTX returned +6.5% a year vs +5.3% for ETHSX.
Updated Nov 19, 2026
PHSTX vs ETHSX side by side
| PHSTX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Franklin Templeton | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 1.04% | 1.18% |
| Annual cost per $10k | $104 | $118 |
| 10-yr cost on $10k (prospectus) | $1,772 | $1,911 |
| Max front load | 5.75% | 5.25% |
| 12b-1 fee | 0.25% | 0.25% |
| 1-yr return | −4.6% | −1.9% |
| 5-yr return (annualized) | +6.5% | +5.3% |
| 10-yr return (annualized) | +6.9% | +6.4% |
| Best quarter | +17.5% | +14.2% |
| Worst quarter | −12.3% | −12.1% |
| Net assets (fund) | $1.5B | $757.9M |
| Number of holdings | 115 | 42 |
| Portfolio turnover | 67% | 3% |
| Returns as of | Dec 31, 2024 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PHSTX | ETHSX | Difference |
|---|---|---|---|
| 2024 | +1.3% | +3.5% | −2.3% |
| 2023 | +9.0% | +5.7% | +3.4% |
| 2022 | −4.7% | −9.4% | +4.7% |
| 2021 | +19.4% | +22.1% | −2.6% |
| 2020 | +15.9% | +13.0% | +2.9% |
| 2019 | +30.2% | +26.0% | +4.2% |
| 2018 | −0.6% | +6.0% | −6.6% |
| 2017 | +15.3% | +16.2% | −1.0% |
| 2016 | −11.7% | −14.9% | +3.2% |
| 2015 | +7.5% | +8.4% | −0.9% |
Source: Fund prospectus bar charts
Holdings overlap
16 of PHSTX's top 25 holdings also appear in ETHSX's top 25.
| Holding | PHSTX | ETHSX |
|---|---|---|
| Eli Lilly & Co. | 13.15% | 12.47% |
| Johnson & Johnson | 8.46% | 6.45% |
| UnitedHealth Group, Inc. | 6.93% | 5.49% |
| AbbVie, Inc. | 6.05% | 6.46% |
| Novartis AG | 5.13% | 1.65% |
| Merck & Co., Inc. | 4.88% | 5.08% |
| AstraZeneca plc | 4.67% | 6.24% |
| Thermo Fisher Scientific, Inc. | 4.50% | 2.79% |
| Intuitive Surgical, Inc. | 4.04% | 2.72% |
| Sanofi SA | 3.23% | 2.95% |
| Roche Holding AG | 2.79% | 5.44% |
| Gilead Sciences, Inc. | 2.63% | 3.34% |
| Vertex Pharmaceuticals, Inc. | 1.97% | 3.38% |
| Novo Nordisk A/S | 1.90% | 1.71% |
| Boston Scientific Corp. | 1.80% | 2.18% |
Source: SEC Form N-PORT
PHSTX top 10
- Eli Lilly & Co. — 13.15%
- Johnson & Johnson — 8.46%
- UnitedHealth Group, Inc. — 6.93%
- AbbVie, Inc. — 6.05%
- Novartis AG — 5.13%
- Merck & Co., Inc. — 4.88%
- AstraZeneca plc — 4.67%
- Thermo Fisher Scientific, Inc. — 4.50%
- Intuitive Surgical, Inc. — 4.04%
- Sanofi SA — 3.23%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between PHSTX and ETHSX?
Which is cheaper, PHSTX or ETHSX?
Should I own both PHSTX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.